These 2 Stocks Have More Upside
Shares of Eli Lilly (NYSE: LLY) have risen 400% over the past five years. Novo Nordisk (NYSE: NVO)…
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly’s and Novo’s GLP-1 Duopoly
You probably already know that pharmaceutical powerhouses Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) dominate the…
Should You Forget CVS Health and Invest in a Purer Healthcare Play?
Key Points CVS Health has a far more diversified business than Novo Nordisk. Both approaches have perks and…
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock’s Surprise Move
Key Points Hims & Hers’ stock is up after ending its lawsuit with Novo Nordisk. The deal shows…
Novo Nordisk Expands Pediatric Reach And Oral Pipeline As Valuation Lags
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. FDA…
Is Novo Nordisk Stock a Bargain Right Now?
The big story in the pharmaceutical sector has been the emergence of GLP-1 weight-loss drugs. Novo Nordisk (NYSE:…
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Key Points Eli Lilly’s stock price rose sharply as demand for its GLP-1 drugs increased. Novo Nordisk is…
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?
Eli Lilly’s (NYSE: LLY) obesity drug, Zepbound, generated sales of $13.5 billion in 2025. Its Type 2 diabetes…
Amazon Is Now Offering Novo Nordisk’s Wegovy Pill in Its Pharmacy. Here’s How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.
The headline-grabbing battle in the GLP-1 space pits pharmaceutical giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE:…